Publication | Closed Access

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

UrologyOverall SurvivalGenitourinary CancerMedicineCancer ManagementSecondary OutcomesPharmacotherapyCancer TreatmentProstatic DiseaseOncologyRadiation Oncology